CeriBell (NASDAQ:CBLL) Reaches New 1-Year High on Analyst Upgrade

CeriBell (NASDAQ:CBLL) shares hit a new 52-week high during mid-day trading on Monday after TD Cowen raised their price target on the stock from $31.00 to $36.00. TD Cowen currently has a buy rating on the stock. CeriBell traded as high as $31.82 and last traded at $31.82, with a volume of 9376 shares. The stock had previously closed at $30.24.

Several other analysts have also recently weighed in on the stock. Canaccord Genuity Group increased their price target on shares of CeriBell from $31.00 to $33.00 and gave the company a “buy” rating in a research note on Monday. Bank of America assumed coverage on CeriBell in a research note on Tuesday, November 5th. They set a “buy” rating and a $32.00 target price for the company. Canaccord Genuity Group started coverage on CeriBell in a report on Tuesday, November 5th. They set a “buy” rating and a $30.00 price target for the company. JPMorgan Chase & Co. initiated coverage on shares of CeriBell in a research note on Tuesday, November 5th. They set an “overweight” rating and a $32.00 target price for the company. Finally, William Blair began coverage on shares of CeriBell in a report on Tuesday, November 5th. They issued an “outperform” rating on the stock. Six research analysts have rated the stock with a buy rating, According to MarketBeat, CeriBell presently has a consensus rating of “Buy” and an average target price of $32.60.

CeriBell Price Performance

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($1.85) EPS for the quarter, missing the consensus estimate of ($0.82) by ($1.03). The firm had revenue of $17.20 million during the quarter, compared to analyst estimates of $17.06 million. As a group, sell-side analysts expect that CeriBell will post -2.46 EPS for the current fiscal year.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.